abrdn Life Sciences Investors (NYSE:HQL) Sees Large Increase in Short Interest

abrdn Life Sciences Investors (NYSE:HQL) was the target of a large increase in short interest during the month of September. As of September 30th, there was short interest totaling 112,812 shares, an increase of 67.3% from the September 15th total of 67,415 shares. Based on an average trading volume of 112,776 shares, the days-to-cover ratio is presently 1.0 days. Currently, 0.4% of the company’s shares are sold short.

abrdn Life Sciences Investors Trading Up 0.6%

Shares of HQL stock opened at $17.24 on Friday. abrdn Life Sciences Investors has a fifty-two week low of $15.66 and a fifty-two week high of $22.67. The business’s 50 day moving average price is $19.86 and its 200-day moving average price is $18.82.

abrdn Life Sciences Investors Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, September 30th. Stockholders of record on Monday, August 24th were given a $0.62 dividend. This represents a $2.48 annualized dividend and a dividend yield of 14.4%. The ex-dividend date of this dividend was Monday, August 24th.

Hedge Funds Weigh In On abrdn Life Sciences Investors

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Independent Financial Group LLC purchased a new position in abrdn Life Sciences Investors in the 1st quarter worth about $211,000. WNY Asset Management LLC bought a new position in abrdn Life Sciences Investors during the 1st quarter valued at about $239,000. Citadel Advisors LLC purchased a new stake in shares of abrdn Life Sciences Investors during the 2nd quarter valued at about $287,000. Wedbush Securities Inc. boosted its holdings in shares of abrdn Life Sciences Investors by 50.6% during the 2nd quarter. Wedbush Securities Inc. now owns 15,960 shares of the company’s stock valued at $319,000 after acquiring an additional 5,360 shares during the last quarter. Finally, NewEdge Advisors LLC boosted its holdings in shares of abrdn Life Sciences Investors by 17.6% during the 1st quarter. NewEdge Advisors LLC now owns 23,788 shares of the company’s stock valued at $387,000 after acquiring an additional 3,562 shares during the last quarter. 32.21% of the stock is owned by institutional investors.

abrdn Life Sciences Investors Company Profile

abrdn Life Sciences Investors (NYSE: HQL) is a diversified, closed-end investment company focused on the life sciences sector. The fund seeks long-term capital appreciation by investing in companies involved in biotechnology, pharmaceuticals, medical devices, diagnostics, healthcare services and related industries.

Its portfolio may include both publicly traded and privately held businesses across various stages of development, from emerging companies developing new therapies and technologies to more established healthcare enterprises.